<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology of malignant pleural mesothelioma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology of malignant pleural mesothelioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology of malignant pleural mesothelioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel H Sterman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leslie A Litzky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry R Kaiser, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Nicholson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Jett, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Vallières, MD, FRCSC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mesothelioma is an insidious neoplasm arising from the mesothelial surfaces of the pleural and peritoneal cavities, the tunica vaginalis, or the pericardium. Eighty percent of cases are pleural in origin. The predominant cause of malignant mesothelioma is inhalational exposure to asbestos, with approximately 70 percent of cases of pleural mesothelioma being associated with documented asbestos exposure.</p><p>This topic will discuss the epidemiology and risk factors of pleural mesothelioma.</p><p class="bulletIndent1"><span class="glyph">●</span>The pathology, clinical presentation, evaluation, and staging, and treatment of malignant pleural mesothelioma are discussed separately. (See  <a class="medical medical_review" href="/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/d/html/4608.html" rel="external">"Pathology of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peritoneal mesothelioma is discussed separately. (See  <a class="medical medical_review" href="/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging"</a> and  <a class="medical medical_review" href="/d/html/82913.html" rel="external">"Malignant peritoneal mesothelioma: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The annual incidence of mesothelioma in the United States is estimated to be approximately 3300 cases per year [<a href="#rid1">1</a>]. The incidence of mesothelioma in the United States peaked around the year 2000 and is now declining, secondary to control of exposure to asbestos [<a href="#rid2">2</a>].</p><p>The incidence is increasing in many other places in the world, particularly in Great Britain and Australia [<a href="#rid3">3,4</a>]. The rate has been predicted to peak around 2015 in England, and mesothelioma rates are expected to drop gradually thereafter. These changes are attributed to an understanding of the relationship of mesothelioma to asbestosis and reduced exposure in the workplace and the general environment. In contrast, mesothelioma incidence rates are predicted to increase dramatically in resource-limited settings secondary to poor regulation of asbestos mining and the proliferation of industrial and household utilization of asbestos [<a href="#rid3">3,5,6</a>].</p><p class="headingAnchor" id="H383327781"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Asbestos exposure is the most important risk factor associated with subsequent development of pleural mesothelioma, and asbestos exposure is responsible for the bulk of the mesothelioma burden worldwide.</p><p class="headingAnchor" id="H3"><span class="h2">Asbestos exposure</span><span class="headingEndMark"> — </span>Asbestos is the commercial name for a group of hydrated magnesium silicate fibrous minerals. Asbestos occurs in soil and rock as long fibers. There are two major types: serpentine and amphibole. About 95 percent of the asbestos produced and used worldwide is chrysotile, which is a serpentine fiber that is reportedly less carcinogenic [<a href="#rid3">3,7</a>]. However, even chrysotile asbestos has been linked to the development of pleural mesothelioma [<a href="#rid7">7</a>].</p><p>Asbestos is valued in industry for its resistance to heat and combustion. It is used in cement, ceiling and pool tiles, automobile brake linings, and in shipbuilding. In addition to occupational exposure, environmental exposure to asbestos from natural sources may contribute to the mesothelioma burden.</p><p class="headingAnchor" id="H383327975"><span class="h3">Occupational exposure</span><span class="headingEndMark"> — </span>Efforts to control occupational exposure to asbestos can result in a significant decrease in the incidence of mesothelioma. The latency period after exposure to asbestos is very prolonged, with almost all cases appearing 15 or more years after exposure [<a href="#rid8">8</a>], and the risk persists for many decades. However, the very prolonged latency between exposure and disease development means that a decrease in the incidence of mesothelioma occurs very slowly.</p><p>As an example, in the United States, as many as eight million living persons in the have been occupationally exposed to asbestos over the past 50 years. The Occupational Safety and Health Administration (OSHA) initially established 5 fibers/mL of air as the standard acceptable exposure. This level has since been reduced to 0.1/mL, but this applies only to fibers longer than 5 micrometers [<a href="#rid9">9</a>]. Workers exposed to higher concentrations of regulated fibers are mandated to use protective clothing, respirators, and showers.</p><p>Asbestos workers are at significant risk for the development of both non-malignant and malignant pulmonary disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 8 percent of asbestos workers will die of respiratory failure secondary to asbestosis. (See  <a class="medical medical_review" href="/d/html/4307.html" rel="external">"Asbestos-related pleuropulmonary disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The average asbestos worker has a 50 percent chance of dying from a malignancy, compared with around 18 percent for the average American. The vast majority of cancers in asbestos workers involve the lung, either primary lung carcinoma or mesothelioma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lifetime risk of developing mesothelioma among asbestos workers is thought to be as high as 10 percent [<a href="#rid10">10</a>]. There is a latency period of approximately 30 to 40 years from the time of asbestos exposure to the development of mesothelioma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There appears to be a dose-response relationship between asbestos exposure and mesothelioma. This was illustrated in cohort study of 4659 people who resided in an Australian city that produced crocidolite asbestos but who did not directly participate in its mining or milling; the incidence of mesothelioma increased significantly with greater environmental exposure, based upon the neighborhood and duration of residence [<a href="#rid11">11</a>]. In a cohort of textile workers with heavy exposure to asbestos, the risk of pleural mesothelioma was increased and was proportional to the latency period [<a href="#rid12">12</a>]. Unlike asbestosis, even a brief intense exposure to asbestos can result in mesothelioma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asbestos exposure acts synergistically with cigarette smoking to increase the risk of developing lung cancer 60 times over that of a similarly matched non-smoking, non-asbestos-exposed cohort. (See  <a class="medical medical_review" href="/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asbestos workers may also be at increased risk of non-mesothelioma gastrointestinal malignancies [<a href="#rid5">5,6,13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of heavy asbestos use in Italy until 1992 when it was banned, there was an epidemic of asbestos-related diseases. The Italian National Registry of Malignant Mesotheliomas collects data of mesothelioma incidence with a regional structure. The type of exposure was an occupational exposure in almost 70 percent of evaluated cases [<a href="#rid15">15</a>]. The Italian surveillance experience has been key in assessing and monitoring the public health impact of occupational and/or environmental exposures, allowing for the implementation of preventive interventions.</p><p></p><p class="headingAnchor" id="H383327969"><span class="h3">Nonoccupational exposure</span><span class="headingEndMark"> — </span>Environmental, nonoccupational exposure to asbestos also can contribute to an increased risk of mesothelioma [<a href="#rid16">16-21</a>].</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In certain rural areas in Greece, Turkey, and Bulgaria, soil contains remarkably high levels of tremolite asbestos fibers, and many cases of mesothelioma in these regions appear to be secondary to long-term nonoccupational asbestos exposure [<a href="#rid16">16-19,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A role for nonoccupational exposure to asbestos was also supported by a study from California in which an increased incidence of mesothelioma was associated with proximity to naturally-occurring asbestos deposits [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhalation of other fibrous silicates, such as erionite, has also been implicated as a potential cause of malignant pleural mesothelioma, as shown in epidemiologic studies of a region in Turkey (Cappadocia), which show an abnormally high incidence of pleural mesothelioma [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluoro-edenite is a naturally-occurring mineral that forms amphibole asbestos fibers. Unpaved roads in Biancavilla, Sicily, Italy, are a source of airborne fibers and have been linked epidemiologically with the development of mesothelioma, in the absence of occupational exposure [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the decrease in asbestos production and the recognition of the connection between asbestos and MPM, there remains the possibility of environmental exposure, an area where the relationship with MPM has not been extensively explored. This potential connection is all the more difficult to establish due to lack of reliable assessment of type and amount of exposure, smaller sample size, and smaller effect sizes compared with those seen in occupational studies. One review summarizes the most recent studies on the relationship between environmental exposure to asbestos and MPM in an attempt to identify features associated with this type of exposure and quantify the association with MPM [<a href="#rid25">25</a>].</p><p></p><p>A literature review and meta-analysis that looked at 18 studies from 12 countries concluded that the risk of MPM from nonoccupational asbestos exposure is consistent with the fiber-type potency response observed in occupational settings. This relationship allows for a better evaluation of the risk of MPM in communities with ambient asbestos exposures from industrial or other sources [<a href="#rid26">26</a>]. </p><p>The epidemiology of sex differences in mesothelioma incidence has not been well studied, recognizing that the majority of occupational exposure occurs among males. In a study of mesothelioma in Italy utilizing an national register epidemiologic surveillance system, cases among females are due mainly to nonoccupational asbestos exposure. Occupational exposures among women mainly are related to work in the chemical and plastic industry in addition to work in the non-asbestos textile sector [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Radiation</span><span class="headingEndMark"> — </span>Ionizing radiation to supradiaphragmatic fields may be a risk factor for the subsequent development of mesothelioma, with a long latent period between the initial treatment and the diagnosis of the second malignancy.</p><p class="bulletIndent1"><span class="glyph">●</span>Two large studies from the Surveillance, Epidemiology, and End Results (SEER) database found that survivors of Hodgkin lymphoma and non-Hodgkin lymphoma were at increased risk for mesothelioma [<a href="#rid28">28,29</a>]. The increased risk was limited to those who had received radiation as part of their treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based series of over 40,000 men treated for testicular cancer between 1943 and 2001 and followed long-term found 10 excess cases of pleural mesothelioma (relative risk 4) for men treated with radiation therapy alone [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The data for patients with breast cancer are conflicting. An analysis of 22,140 patients treated in 11 National Surgical Adjuvant Breast Project (NSABP) trials identified three cases of mesothelioma, all occurring in women who had received radiation therapy to the ipsilateral thorax [<a href="#rid31">31</a>]. In contrast, a SEER database cohort of over 250,000 could not identify a link between radiation therapy and subsequent development of pleural mesothelioma [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although prophylactic mediastinal irradiation is no longer used in testicular germ cell tumors and its use has been sharply curtailed in patients with Hodgkin lymphoma and non-Hodgkin lymphoma, there are a substantial number of cancer survivors who remain at risk for the late development of mesothelioma. (See  <a class="medical medical_review" href="/d/html/4754.html" rel="external">"Treatment of favorable prognosis early (stage I-II) classic Hodgkin lymphoma"</a>.)</p><p></p><p>Malignant mesothelioma developing after therapeutic irradiation may have somewhat different features compared with those due to asbestos exposure. In one report, 22 patients who developed mesothelioma following chest irradiation as part of their treatment for Hodgkin disease or non-Hodgkin lymphoma were compared with 1596 cases associated with asbestos exposure [<a href="#rid33">33</a>]. Patients with treatment-related mesothelioma were significantly younger (median age 45 versus 64 years) and had a significantly longer overall survival (32.5 versus 12.7 months).</p><p>The development of malignant pleural mesothelioma has also been associated with other sources of radiation exposure. In one study, exposure to external radiation at nuclear facilities was associated with a significant increase in mesothelioma risk [<a href="#rid34">34</a>]. In rare cases malignant pleural mesothelioma has been associated with intrapleural thorium dioxide (Thorotrast), a radioactive contrast agent in the 1930s and 1940s [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Carbon nanotubes</span><span class="headingEndMark"> — </span>Carbon nanotubes share similar dimensions and chemical properties with asbestos [<a href="#rid36">36</a>]. Studies in animal models have shown that these particles can induce mesothelioma-like changes in susceptible strains of mice following intraperitoneal administration [<a href="#rid37">37,38</a>].</p><p>Carbon nanotubes are being used in an increasing array of applications in the workplace. Epidemiologic vigilance will be required to ensure that these are not a new etiologic source of malignant mesothelioma [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Viral oncogenes</span><span class="headingEndMark"> — </span>Simian virus 40 (SV40) is a polyomavirus with oncogenic potential in humans. Its actions in mesothelioma are thought to be due to the complex formation of viral tumor antigens (Tag) and p53 [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/8280.html" rel="external">"Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections"</a>.)</p><p>The relationship between SV40 and mesothelioma remains uncertain. Several studies identified SV40 nucleic acids in a large proportion of mesothelioma cases (some of which did not have obvious asbestos exposure) [<a href="#rid40">40-42</a>]. However, a number of epidemiologic studies have failed to confirm these observations [<a href="#rid43">43-45</a>].</p><p class="headingAnchor" id="H1416281290"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Familial clustering of pleural mesothelioma has been noted, with one study describing an elevated risk for mesothelioma among those whose parents or siblings were diagnosed with the disease of 3.9- and 12.4-fold, respectively [<a href="#rid46">46</a>].</p><p>Regarding specific genes that have been implicated, inactivation of the nuclear deubiquitinase <em>BAP1</em> is associated with malignant mesothelioma [<a href="#rid47">47</a>]. <em>BAP1</em> appears to regulate key histones and transcription factors related to the development of tumors [<a href="#rid48">48,49</a>]. In an initial study, inactivating mutations of <em>BAP1</em> were found in about one-quarter of mesothelioma tumor tissues tested [<a href="#rid50">50</a>]. More recent data suggest that somatic mutations of <em>BAP1</em> may be present in up to 60 percent of mesotheliomas. In addition, germline mutations in <em>BAP1</em> were identified in two families with a high incidence of mesothelioma [<a href="#rid51">51</a>]. Loss of <em>BAP1</em> may predispose to cancer after asbestos exposure; testing for mutations in this gene might eventually be used to identify patients at high risk who could be targeted for early intervention. Loss of <em>BAP1</em> seems to be part of a larger familial cancer susceptibility syndrome, most often associated with ocular melanoma.</p><p class="headingAnchor" id="H2226328266"><span class="h2">Other possible causes</span><span class="headingEndMark"> — </span>Most cases of mesothelioma not related to asbestos are idiopathic. However, in certain geographic areas, mineral fibers other than asbestos (eg, erionite, fluoro-edenite) have been linked to mesothelioma [<a href="#rid52">52,53</a>]. Therapeutic radiation for other malignancies is another risk factor [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H107945732"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83057.html" rel="external">"Patient education: Asbestos exposure (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The predominant cause of asbestosis is inhalational exposure to asbestos. There is a very prolonged latency period between exposure to asbestos and the development of mesothelioma. (See <a class="local">'Asbestos exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of the relationship between asbestos exposure and mesothelioma and other lung malignancies led to sharp restrictions in environmental exposure to asbestos. In the United States, these restrictions have led to a gradual decrease in the total number of cases. In other areas, such as Great Britain, the number of cases continues to increase, and the peak incidence has not yet been reached. (See <a class="local">'Asbestos exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to ionizing radiation to supradiaphragmatic fields in the treatment of malignancy (Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer) has also been associated with a statistically significant increase in the risk of mesothelioma, although this accounts for only a small fraction of the mesothelioma cases diagnosed. (See <a class="local">'Radiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A genetic predisposition for mesothelioma has been identified (mutation in the gene <em>BAP1</em>) that has been associated with other cancers, especially ocular melanoma. (See <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="headingAnchor" id="H1456516552"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Steven M Albelda, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008; 17:525.</a></li><li><a class="nounderline abstract_t">Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145:211.</a></li><li><a class="nounderline abstract_t">Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92:587.</a></li><li><a class="nounderline abstract_t">Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012; 1:491.</a></li><li><a class="nounderline abstract_t">Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.</a></li><li><a class="nounderline abstract_t">Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin Proc 1988; 63:1234.</a></li><li class="breakAll">Asbestos and cancer risk. http://www.cancer.org/cancer/cancercauses/othercarcinogens/intheworkplace/asbestos (Accessed on January 02, 2020).</li><li><a class="nounderline abstract_t">Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34:718.</a></li><li class="breakAll">Asbestos. Occupational Safety and Health Administration. United States Department of Labor. https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&amp;p_id=9995 (Accessed on October 17, 2013).</li><li><a class="nounderline abstract_t">Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 46:2736.</a></li><li><a class="nounderline abstract_t">Hansen J, de Klerk NH, Musk AW, Hobbs MS. Environmental exposure to crocidolite and mesothelioma: exposure-response relationships. Am J Respir Crit Care Med 1998; 157:69.</a></li><li><a class="nounderline abstract_t">Pira E, Pelucchi C, Buffoni L, et al. Cancer mortality in a cohort of asbestos textile workers. Br J Cancer 2005; 92:580.</a></li><li><a class="nounderline abstract_t">Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 1983; 77:321.</a></li><li><a class="nounderline abstract_t">Mossman BT. Carcinogenesis and related cell and tissue responses to asbestos: a review. Ann Occup Hyg 1994; 38:617.</a></li><li><a class="nounderline abstract_t">Marinaccio A, Corfiati M, Binazzi A, et al. The epidemiological surveillance of malignant mesothelioma in Italy (1993-2015): methods, findings, and research perspectives. Epidemiol Prev 2020; 44:23.</a></li><li><a class="nounderline abstract_t">Metintas M, Ozdemir N, Hillerdal G, et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 1999; 93:349.</a></li><li><a class="nounderline abstract_t">Senyiğit A, Babayiğit C, Gökirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 2000; 67:610.</a></li><li><a class="nounderline abstract_t">Senyiğit A, Bayram H, Babayiğit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration 2000; 67:615.</a></li><li><a class="nounderline abstract_t">Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002; 122:2224.</a></li><li><a class="nounderline abstract_t">Pan XL, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005; 172:1019.</a></li><li><a class="nounderline abstract_t">Gennaro V, Ugolini D, Viarengo P, et al. Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002). Eur J Cancer 2005; 41:2709.</a></li><li><a class="nounderline abstract_t">Bayram M, Dongel I, Bakan ND, et al. High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites. Chest 2013; 143:164.</a></li><li><a class="nounderline abstract_t">Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007; 7:147.</a></li><li><a class="nounderline abstract_t">Bruno C, Tumino R, Fazzo L, et al. Incidence of pleural mesothelioma in a community exposed to fibres with fluoro-edenitic composition in Biancavilla (Sicily, Italy). Ann Ist Super Sanita 2014; 50:111.</a></li><li><a class="nounderline abstract_t">Liu B, van Gerwen M, Bonassi S, et al. Epidemiology of Environmental Exposure and Malignant Mesothelioma. J Thorac Oncol 2017; 12:1031.</a></li><li><a class="nounderline abstract_t">Marsh GM, Riordan AS, Keeton KA, Benson SM. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Occup Environ Med 2017; 74:838.</a></li><li><a class="nounderline abstract_t">Pavlisko EN, Liu B, Green C, et al. Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases. Am J Surg Pathol 2020; 44:293.</a></li><li><a class="nounderline abstract_t">Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107:108.</a></li><li><a class="nounderline abstract_t">Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007; 109:1432.</a></li><li><a class="nounderline abstract_t">Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354.</a></li><li><a class="nounderline abstract_t">Deutsch M, Land SR, Begovic M, et al. An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. Am J Clin Oncol 2007; 30:294.</a></li><li><a class="nounderline abstract_t">Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 1997; 80:948.</a></li><li><a class="nounderline abstract_t">Chirieac LR, Barletta JA, Yeap BY, et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol 2013; 31:4544.</a></li><li><a class="nounderline abstract_t">Gibb H, Fulcher K, Nagarajan S, et al. Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health 2013; 103:710.</a></li><li><a class="nounderline abstract_t">Andersson M, Wallin H, Jönsson M, et al. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int J Cancer 1995; 63:330.</a></li><li><a class="nounderline abstract_t">The Lancet Oncology . Space elevators, tennis racquets, and mesothelioma. Lancet Oncol 2008; 9:601.</a></li><li><a class="nounderline abstract_t">Takagi A, Hirose A, Nishimura T, et al. Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008; 33:105.</a></li><li><a class="nounderline abstract_t">Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008; 3:423.</a></li><li><a class="nounderline abstract_t">Bocchetta M, Eliasz S, De Marco MA, et al. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008; 68:1022.</a></li><li><a class="nounderline abstract_t">Comar M, Zanotta N, Pesel G, et al. Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy. Tumori 2012; 98:210.</a></li><li><a class="nounderline abstract_t">Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005; 65:3049.</a></li><li><a class="nounderline abstract_t">De Rienzo A, Tor M, Sterman DH, et al. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem 2002; 84:455.</a></li><li><a class="nounderline abstract_t">Lundstig A, Dejmek A, Eklund C, et al. No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden. Anticancer Res 2007; 27:4159.</a></li><li><a class="nounderline abstract_t">Ziegler A, Seemayer CA, Hinterberger M, et al. Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung Cancer 2007; 57:282.</a></li><li><a class="nounderline abstract_t">Manfredi JJ, Dong J, Liu WJ, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005; 65:2602.</a></li><li><a class="nounderline abstract_t">Ji J, Sundquist J, Sundquist K. Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study. Eur Respir J 2016; 48:873.</a></li><li><a class="nounderline abstract_t">Panou V, Gadiraju M, Wolin A, et al. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol 2018; 36:2863.</a></li><li><a class="nounderline abstract_t">Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer 2013; 13:153.</a></li><li><a class="nounderline abstract_t">Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012; 10:179.</a></li><li><a class="nounderline abstract_t">Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43:668.</a></li><li><a class="nounderline abstract_t">Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43:1022.</a></li><li><a class="nounderline abstract_t">Demirer E, Ghattas CF, Radwan MO, Elamin EM. Clinical and prognostic features of erionite-induced malignant mesothelioma. Yonsei Med J 2015; 56:311.</a></li><li><a class="nounderline abstract_t">Attanoos RL, Churg A, Galateau-Salle F, et al. Malignant Mesothelioma and Its Non-Asbestos Causes. Arch Pathol Lab Med 2018; 142:753.</a></li></ol></div><div id="topicVersionRevision">Topic 4625 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941374" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : US mesothelioma patterns 1973-2002: indicators of change and insights into background rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9012593" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Analysis of current trends in United States mesothelioma incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668716" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23977542" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Malignant pleural mesothelioma: an epidemiological perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8462328" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Natural history and epidemiology of malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3059081" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Malignant mesothelioma of the pleura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3059081" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Malignant mesothelioma of the pleura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1494965" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Latent period for malignant mesothelioma of occupational origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1494965" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Latent period for malignant mesothelioma of occupational origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7448712" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Latency of asbestos disease among insulation workers in the United States and Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445280" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Environmental exposure to crocidolite and mesothelioma: exposure-response relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15702125" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cancer mortality in a cohort of asbestos textile workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6357260" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Malignant mesothelioma 1982: review of 4710 published cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978984" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Carcinogenesis and related cell and tissue responses to asbestos: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374111" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The epidemiological surveillance of malignant mesothelioma in Italy (1993-2015): methods, findings, and research perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10464903" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Environmental asbestos exposure and malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124642" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124643" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475867" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976368" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Residential proximity to naturally occurring asbestos and mesothelioma risk in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243515" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22814683" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251920" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24968908" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidence of pleural mesothelioma in a community exposed to fibres with fluoro-edenitic composition in Biancavilla (Sicily, Italy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28412495" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiology of Environmental Exposure and Malignant Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935666" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31876584" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16708354" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17315168" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Therapeutic radiation for lymphoma: risk of malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174857" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551308" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307196" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Incidence of malignant pleural mesothelioma after thoracic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24248693" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23409888" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7591226" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18598922" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Space elevators, tennis racquets, and mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303189" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18654567" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281476" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22677986" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15833832" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11813251" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18225586" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513005" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805256" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evidence against a role for SV40 in human mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27174879" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113886" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23550303" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : BAP1 and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935333" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642991" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874000" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Germline BAP1 mutations predispose to malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25683976" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical and prognostic features of erionite-induced malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480760" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Malignant Mesothelioma and Its Non-Asbestos Causes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
